Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Orladeyo™ (berotralstat) – New orphan drug approval
December 3, 2020 - BioCryst Pharmaceuticals announced the FDA approval of Orladeyo (berotralstat), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.
